CAMBRIDGE, Mass., Oct. 6, 2011 /PRNewswire/ -- Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced the publication of a paper in PLoS ONE demonstrating the development and validation of the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, Galenea's proprietary technology that enables high throughput screening ... read more

CAMBRIDGE, Mass., Sept. 28, 2011 /PRNewswire/ -- Galenea Corp. has been awarded two Small Business Innovation Research (SBIR) grants to further their work towards discovering and developing breakthrough therapeutics for the cognitive deficits associated with schizophrenia. These latest awards from the National Institute of Mental Health will support two ... read more

CAMBRIDGE, Mass. and NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to Huntington's disease (HD) utilizing Galenea's proprietary synaptic transmission drug discovery platform. Mounting evidence indicates that mutant huntingtin protein, the molecular defect in HD, ... read more